If you have an elevated PSA (Prostate Specific Antigen) after a radical retropubic prostatectomy (RRP), you may be eligible to participate in one of these research studies.
#1: A randomized, controlled, open-label trial of Degarelix intermittent therapy vs. continuous androgen deprivation therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy.
For additional information go to: www.ferring.com
Research Locations:
Towson, MD
Physicians Pavilion North
6535 North Charles St., Suite 625
Baltimore, MD 21204
Contact Heather Thomas, hthomas@cua.md or 410-825-5454
Glen Burnie, MD
806 Landmark Dr., Suite 118
Glen Burnie, MD 21061
Contact Virginia Michaels, vmichaels@cua.md or 410-760-9400
Franklin Square
6830 Hospital Dr., Suite 204
Baltimore, MD 21237
Contact Angela Somers, asomers@cua.md or 410-391-6131 x1212
#2: A randomized, open label, multicenter, Phase III, 2-arm study of androgen withdrawal with Leuprolide, +/- Docetaxel for clinically asymptomatic prostate cancer subjects with a rising PSA following definitive local therapy.
For additional information go to: www.sanofi-aventis.com
Research Location:
Towson, MD
Physicians Pavilion North
6535 North Charles St., Suite 625
Baltimore, MD 21204
Contact Heather Thomas, hthomas@cua.md or 410-825-5454
|
 |
|
« Current Clinical Trials
|
|
|
|
Erectile Dysfunction (ED)
|
|
|
|
Enlarged Prostate: (Benign Prostatic Hyperplasia/BPH)
|
|
|
|
Bladder Cancer
|
|
|
|
Prostate Cancer
|
|
|
|
Overactive Bladder
|
|